Multifunctional Tumor-Targeted Nanoparticles for Lung Cancer

2012 ◽  
pp. 15-44 ◽  
Author(s):  
Shinji Kuroda ◽  
Tomohisa Yokoyama ◽  
Justina Tam ◽  
Ailing Scott ◽  
Li Ma ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Targeted Nanoparticles

scholarly journals Targeted Nanoparticles Harboring Jasmine-Oil-Entrapped Paclitaxel for Elimination of Lung Cancer Cells

2021 ◽  
Vol 22 (3) ◽  
pp. 1019
Author(s):  
Shira Engelberg ◽  
Yuexi Lin ◽  
Yehuda G. Assaraf ◽  
Yoav D. Livney
Keyword(s):  
Lung Cancer ◽  
Targeted Drug Delivery ◽  
A549 Cells ◽  
Average Diameter ◽  
Delivery Systems ◽  
Small Cell Lung ◽  
Targeted Nanoparticles ◽  
Ic50 Value ◽  
Residual Amount ◽  
Human Nsclc

Selectively targeted drug delivery systems are preferable chemotherapeutic platforms, as they specifically deliver the drug cargo into tumor cells, while minimizing untoward toxic effects. However, these delivery systems suffer from insufficient encapsulation efficiency (EE), encapsulation capacity (EC), and premature drug release. Herein, we coencapsulated paclitaxel (PTX) and Jasmine oil (JO) within PEG-PCL nanoparticles (NPs), with an average diameter < 50 nm, selectively targeted to non-small cell lung cancer (NSCLC) cells, via S15-aptamer (APT) decoration. JO was selected as an “adhesive” oily core to enhance PTX entrapment, as JO and PTX share similar hydrophobicity and terpenoid structure. JO markedly enhanced EE of PTX from 23% to 87.8% and EC from 35 ± 6 to 74 ± 8 µg PTX/mg PEG-PCL. JO also markedly increased the residual amount of PTX after 69 h, from 18.3% to 65%. Moreover, PTX cytotoxicity against human NSCLC A549 cells was significantly enhanced due to the co-encapsulation with JO; the IC50 value for PTX encapsulated within JO-containing APT-NPs was 20-fold lower than that for APT-NPs lacking JO. Remarkably, JO-containing APT-NPs displayed a 6-fold more potent cell-killing, relatively to the free-drug. Collectively, these findings reveal a marked synergistic contribution of JO to the cytotoxic activity of APT-NP-based systems, for targeted PTX delivery against NSCLC, which may be readily applied to various hydrophobic chemotherapeutics.

scholarly journals Development of paclitaxel loaded pegylated gelatin targeted nanoparticles for improved treatment efficacy in non-small cell lung cancer (NSCLC): an in vitro and in vivo evaluation study

2021 ◽  
Author(s):  
Minwei Gu ◽  
Jun Luan ◽  
Kun Song ◽  
Cao Qiu ◽  
XiaoLi Zhang ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Small Cell Lung Cancer ◽  
Cell Lines ◽  
Cell Lung Cancer ◽  
Small Cell ◽  
Small Cell Lung ◽  
Targeted Nanoparticles ◽  
Pulmonary Deposition

Purpose: To develop and evaluate paclitaxel (PTX) loaded pegylated gelatin targeted nanoparticles for improved efficacy in non-small cell lung cancer (NSCLC) treatment. Method: PTX loaded gelatin nanoparticles (PTX-GNP) were prepared by crosslinking with glutaraldehyde aqueous solution. These nanoparticles (NPs) were further incubated with PEG 400 to form PEGylated NPs (PEG-PTX-GNP). The NPs were evaluated for surface morphology, size, zeta potential, encapsulation efficiency, drug loading, in vitro drug release, cytotoxicity in an assay on cancer cell lines L132, in vitro cellular uptake in an assay in L132 and 293T cell lines, in vivo antitumor activity on female Balb/c mice, pulmonary deposition, histopathology, and immunohistochemical properties. Results: The nanoparticles were of spherical shape with smooth surface characteristics. The observed DL was of 20.18 to 32.11%, as particle size was of 90 to 115 nm. Zeta potential and polydispersity index (PDI) were within acceptable ranges. Encapsulation was effective when the NPs had a size of 80.50 nm to 98.12 nm. The PEGylated PTX loaded nanoparticles (PEG-PTX-GNP, GNP4) showed similar PTX release profile to that of the NP4 formulation. PEGylated NPs showed the desired PTX release pattern that is required for cancer treatment. In an in vitro cytotoxicity study, PEG-PTX-GNP showed the maximum antiproliferative activity over the period of 24 hours, followed by PTX-GNP, pure PTX and BPEG-GNP. PEG-PTX-GNP showed the highest internalization within both cell lines, followed by PTX-GNP and pure PTX. The survival rate of animals in PEG-PTX-GNP group was 100%, proving the safety and efficacy of the treatment. PEG-PTX-GNP showed the highest antitumor activity as compared to other formulations. The pulmonary deposition rate was the highest (6.5 to 12.55 μg/g) in PEG-PTX-GNP formulations. Histopathology and immunohistochemical study proved that PEG-PTX-GNP had greater anticancer potential than other tested formulations. Conclusion: This study confirms the potential use of paclitaxel loaded PEGylated gelatin targeted nanoparticles for improved efficacy in non-small cell lung cancer (NSCLC) treatment.

Chitosan cross-linked docetaxel loaded EGF receptor targeted nanoparticles for lung cancer cells

2014 ◽  
Vol 69 ◽  
pp. 532-541 ◽  
Author(s):  
S. Maya ◽  
Bruno Sarmento ◽  
Vinoth-Kumar Lakshmanan ◽  
Deepthy Menon ◽  
Vitor Seabra ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Cancer Cells ◽  
Egf Receptor ◽  
Lung Cancer Cells ◽  
Targeted Nanoparticles
Sign in / Sign up

Export Citation Format

Share Document